Drosophila Application in Drug Development
With many years of research experience and efforts in the field of Drosophila, CD BioSciences has acquired all the necessary knowledge and techniques to promote Drosophila as a model organism. We present the application of Drosophila in drug discovery and drug delivery systems.
The advantage of Drosophila in drug development is that it is efficient, rapid and cost effective. These reliable results can advance the progress and translation of later mammalian validation and clinical trials.
First, Drosophila populations are economical and rapidly reproducing, thus are far less costly than mammals as a discovery and validation platform in the early stages of drug development. Second, Drosophila is a well-studied and easily genetically manipulated model organism that has been used to study the molecular mechanisms of human diseases, including central nervous system disorders, inflammatory diseases, cardiovascular diseases, cancer, and diabetes. Therefore, at the genetic and molecular levels, Drosophila can be used as a more accurate multicellular in vivo environment to assess the pharmacokinetics and pharmacodynamics of compounds or to study the molecular mechanisms of small molecule therapies. The results play an important role in effectively advancing the progress of mammalian drug development and reducing false positives.
Drosophila has been used in the initial development of drugs for many diseases. Some of the anti-cancer drugs currently screened using the Drosophila model have already passed mammalian validation and clinical trials, and already have received FDA approval. This is a testament to the potential of Drosophila in drug development. Combined with a strong genetic platform and knowledge of medicinal chemistry, Drosophila has many applications in the drug development process, including drug screening, drug validation, and molecular modification of drugs.
Several novel drug delivery systems allow precise control of release time and targeting of lesions. However, the use of novel materials requires rigorous in vivo kinetic and toxicological evaluation. Drosophila has a highly homologous organ and metabolic pathway to humans, resulting in a small molecule response mechanism similar to that of mammals. It can be directly used to establish the evaluation process of drug delivery systems, including biocompatibility, toxicities, and targeting. In addition, no ethical considerations and high-throughput screening, the Drosophila model can facilitate the rapid development of delivery systems and the study of material small molecule interactions mechanisms.
CD BioSciences Drosophila Center provides specialized drug development solutions for our clients using our Drosophila knowledge and technology platform. Based on the general procedures of drug discovery and validation, we customize a professional Drosophila drug development process to accelerate your project. Our services go beyond these and our technology goes beyond these!
- To meet the needs of all disease and drug target examination, we provide a total Drosophila drug development model customization service.
- We then provide Drosophila in vitro and in vivo drug screening and validation services based on our clients' needs. In addition we provide a variety of phenotypic assay analysis services to optimize monitoring protocols and improve the efficiency of drug development.
CD BioSciences is committed to advancing bioscience technology and drug development using Drosophila. With proven technologies and years of experience in the field of fruit fly, our PhD team conducts one-to-one technical consultancy and Drosophila-based integration services to our clients' projects. Please feel free to contact us starting your private project customization.
- Silindir Gunay M, et al. (2016). Drug delivery systems for imaging and therapy of Parkinson’s disease. Current neuropharmacology, 14(4), 376-391.
- Yadav AK, et al. (2016). Cancer drug development using drosophila as an in vivo tool: from bedside to bench and back. Trends in Pharmacological Sciences, 37(9), 789-806.
- Pappus SA, et al. (2017). A toxicity assessment of hydroxyapatite nanoparticles on development and behaviour of Drosophila melanogaster. Journal of Nanoparticle Research, 19(4), 136.
- Sahlgren C, et al. (2017). Tailored approaches in drug development and diagnostics: from molecular design to biological model systems. Advanced healthcare materials, 6(21), 1700258.
For research use only. Not intended for any clinical use.